These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 19237696)

  • 1. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

  • 2. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis.
    Boggild M; Ford H
    Clin Evid; 2002 Jun; (7):1195-207. PubMed ID: 12230737
    [No Abstract]   [Full Text] [Related]  

  • 4. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
    Lebrun C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis.
    Hawker K; Frohman E
    Prim Care; 2004 Mar; 31(1):201-26. PubMed ID: 15110166
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of progressive forms of multiple sclerosis].
    Edan G
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1008-13. PubMed ID: 11787331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landmark papers in multiple sclerosis.
    Cross AH
    Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
    [No Abstract]   [Full Text] [Related]  

  • 10. [Progress of therapy in patients with multiple sclerosis].
    Kümpfel T; Havla J; Hohlfeld R
    MMW Fortschr Med; 2010 Mar; 152(9):42-4. PubMed ID: 20384096
    [No Abstract]   [Full Text] [Related]  

  • 11. MRI lesion loads and disability relationships in MS: more similar than different?
    Wolinsky JS
    Neurology; 2009 Nov; 73(19):1524-5. PubMed ID: 19828867
    [No Abstract]   [Full Text] [Related]  

  • 12. [New immunomodulator for multiple sclerosis patients. 30% fewer relapse rates].
    MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070870
    [No Abstract]   [Full Text] [Related]  

  • 13. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple sclerosis: between wish and reality].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple sclerosis: spontaneous course, natural history].
    Vukusic S; Moreau T; Bouhour F; Adeleine P; Confavreux C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):753-6. PubMed ID: 11677394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
    Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.